← Back to headlines
Eli Lilly to Acquire CrossBridge Bio to Expand Oncology Pipeline
Eli Lilly is set to acquire CrossBridge Bio, a move aimed at bolstering its oncology drug development pipeline. This acquisition is expected to enhance Eli Lilly's capabilities and offerings in the cancer treatment sector.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
